Improved outcomes in NOD mice treated with a novel Th2 cytokine-biasing NKT cell activator

Claire Forestier, Toshiyuki Takaki, Alberto Molano, Jin S. Im, Ian Baine, Elliot S. Jerud, Petr Illarionov, Rachel Ndonye, Amy R. Howell, Pere Santamaria, Gurdyal S. Besra, Teresa P. DiLorenzo, Steven A. Porcelli

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Activation of CD1d-restricted invariant NKT (iNKT) cells by α-galactosylceramide (αGalCer) significantly suppresses development of diabetes in NOD mice. The mechanisms of this protective effect are complex, involving both Th1 and Th2 cytokines and a network of regulatory cells including tolerogenic dendritic cells. In the current study, we evaluated a newly described synthetic αGalCer analog (C20:2) that elicits a Th2-biased cytokine response for its impact on disease progression and immunopathology in NOD mice. Treatment of NOD mice with αGalCer C20:2 significantly delayed and reduced the incidence of diabetes. This was associated with significant suppression of the late progression of insulitis, reduced infiltration of islets by autoreactive CD8+ T cells, and prevention of progressive disease-related changes in relative proportions of different subsets of dendritic cells in the draining pancreatic lymph nodes. Multiple favorable effects observed with αGalCer C20:2 were significantly more pronounced than those seen in direct comparisons with a closely related analog of αGalCer that stimulated a more mixed pattern of Th1 and Th2 cytokine secretion. Unlike a previously reported Th2-skewing murine iNKT cell agonist, the αGalCer C20:2 analog was strongly stimulatory for human iNKT cells and thus warrants further examination as a potential immunomodulatory agent for human disease.

Original languageEnglish (US)
Pages (from-to)1415-1425
Number of pages11
JournalJournal of Immunology
Volume178
Issue number3
StatePublished - Feb 1 2007

Fingerprint

Galactosylceramides
Inbred NOD Mouse
Natural Killer T-Cells
Cytokines
Dendritic Cells
Disease Progression
Lymph Nodes
T-Lymphocytes
Incidence

ASJC Scopus subject areas

  • Immunology

Cite this

Forestier, C., Takaki, T., Molano, A., Im, J. S., Baine, I., Jerud, E. S., ... Porcelli, S. A. (2007). Improved outcomes in NOD mice treated with a novel Th2 cytokine-biasing NKT cell activator. Journal of Immunology, 178(3), 1415-1425.

Improved outcomes in NOD mice treated with a novel Th2 cytokine-biasing NKT cell activator. / Forestier, Claire; Takaki, Toshiyuki; Molano, Alberto; Im, Jin S.; Baine, Ian; Jerud, Elliot S.; Illarionov, Petr; Ndonye, Rachel; Howell, Amy R.; Santamaria, Pere; Besra, Gurdyal S.; DiLorenzo, Teresa P.; Porcelli, Steven A.

In: Journal of Immunology, Vol. 178, No. 3, 01.02.2007, p. 1415-1425.

Research output: Contribution to journalArticle

Forestier, C, Takaki, T, Molano, A, Im, JS, Baine, I, Jerud, ES, Illarionov, P, Ndonye, R, Howell, AR, Santamaria, P, Besra, GS, DiLorenzo, TP & Porcelli, SA 2007, 'Improved outcomes in NOD mice treated with a novel Th2 cytokine-biasing NKT cell activator', Journal of Immunology, vol. 178, no. 3, pp. 1415-1425.
Forestier C, Takaki T, Molano A, Im JS, Baine I, Jerud ES et al. Improved outcomes in NOD mice treated with a novel Th2 cytokine-biasing NKT cell activator. Journal of Immunology. 2007 Feb 1;178(3):1415-1425.
Forestier, Claire ; Takaki, Toshiyuki ; Molano, Alberto ; Im, Jin S. ; Baine, Ian ; Jerud, Elliot S. ; Illarionov, Petr ; Ndonye, Rachel ; Howell, Amy R. ; Santamaria, Pere ; Besra, Gurdyal S. ; DiLorenzo, Teresa P. ; Porcelli, Steven A. / Improved outcomes in NOD mice treated with a novel Th2 cytokine-biasing NKT cell activator. In: Journal of Immunology. 2007 ; Vol. 178, No. 3. pp. 1415-1425.
@article{194b8186a0e441e2a03018c95143331e,
title = "Improved outcomes in NOD mice treated with a novel Th2 cytokine-biasing NKT cell activator",
abstract = "Activation of CD1d-restricted invariant NKT (iNKT) cells by α-galactosylceramide (αGalCer) significantly suppresses development of diabetes in NOD mice. The mechanisms of this protective effect are complex, involving both Th1 and Th2 cytokines and a network of regulatory cells including tolerogenic dendritic cells. In the current study, we evaluated a newly described synthetic αGalCer analog (C20:2) that elicits a Th2-biased cytokine response for its impact on disease progression and immunopathology in NOD mice. Treatment of NOD mice with αGalCer C20:2 significantly delayed and reduced the incidence of diabetes. This was associated with significant suppression of the late progression of insulitis, reduced infiltration of islets by autoreactive CD8+ T cells, and prevention of progressive disease-related changes in relative proportions of different subsets of dendritic cells in the draining pancreatic lymph nodes. Multiple favorable effects observed with αGalCer C20:2 were significantly more pronounced than those seen in direct comparisons with a closely related analog of αGalCer that stimulated a more mixed pattern of Th1 and Th2 cytokine secretion. Unlike a previously reported Th2-skewing murine iNKT cell agonist, the αGalCer C20:2 analog was strongly stimulatory for human iNKT cells and thus warrants further examination as a potential immunomodulatory agent for human disease.",
author = "Claire Forestier and Toshiyuki Takaki and Alberto Molano and Im, {Jin S.} and Ian Baine and Jerud, {Elliot S.} and Petr Illarionov and Rachel Ndonye and Howell, {Amy R.} and Pere Santamaria and Besra, {Gurdyal S.} and DiLorenzo, {Teresa P.} and Porcelli, {Steven A.}",
year = "2007",
month = "2",
day = "1",
language = "English (US)",
volume = "178",
pages = "1415--1425",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "3",

}

TY - JOUR

T1 - Improved outcomes in NOD mice treated with a novel Th2 cytokine-biasing NKT cell activator

AU - Forestier, Claire

AU - Takaki, Toshiyuki

AU - Molano, Alberto

AU - Im, Jin S.

AU - Baine, Ian

AU - Jerud, Elliot S.

AU - Illarionov, Petr

AU - Ndonye, Rachel

AU - Howell, Amy R.

AU - Santamaria, Pere

AU - Besra, Gurdyal S.

AU - DiLorenzo, Teresa P.

AU - Porcelli, Steven A.

PY - 2007/2/1

Y1 - 2007/2/1

N2 - Activation of CD1d-restricted invariant NKT (iNKT) cells by α-galactosylceramide (αGalCer) significantly suppresses development of diabetes in NOD mice. The mechanisms of this protective effect are complex, involving both Th1 and Th2 cytokines and a network of regulatory cells including tolerogenic dendritic cells. In the current study, we evaluated a newly described synthetic αGalCer analog (C20:2) that elicits a Th2-biased cytokine response for its impact on disease progression and immunopathology in NOD mice. Treatment of NOD mice with αGalCer C20:2 significantly delayed and reduced the incidence of diabetes. This was associated with significant suppression of the late progression of insulitis, reduced infiltration of islets by autoreactive CD8+ T cells, and prevention of progressive disease-related changes in relative proportions of different subsets of dendritic cells in the draining pancreatic lymph nodes. Multiple favorable effects observed with αGalCer C20:2 were significantly more pronounced than those seen in direct comparisons with a closely related analog of αGalCer that stimulated a more mixed pattern of Th1 and Th2 cytokine secretion. Unlike a previously reported Th2-skewing murine iNKT cell agonist, the αGalCer C20:2 analog was strongly stimulatory for human iNKT cells and thus warrants further examination as a potential immunomodulatory agent for human disease.

AB - Activation of CD1d-restricted invariant NKT (iNKT) cells by α-galactosylceramide (αGalCer) significantly suppresses development of diabetes in NOD mice. The mechanisms of this protective effect are complex, involving both Th1 and Th2 cytokines and a network of regulatory cells including tolerogenic dendritic cells. In the current study, we evaluated a newly described synthetic αGalCer analog (C20:2) that elicits a Th2-biased cytokine response for its impact on disease progression and immunopathology in NOD mice. Treatment of NOD mice with αGalCer C20:2 significantly delayed and reduced the incidence of diabetes. This was associated with significant suppression of the late progression of insulitis, reduced infiltration of islets by autoreactive CD8+ T cells, and prevention of progressive disease-related changes in relative proportions of different subsets of dendritic cells in the draining pancreatic lymph nodes. Multiple favorable effects observed with αGalCer C20:2 were significantly more pronounced than those seen in direct comparisons with a closely related analog of αGalCer that stimulated a more mixed pattern of Th1 and Th2 cytokine secretion. Unlike a previously reported Th2-skewing murine iNKT cell agonist, the αGalCer C20:2 analog was strongly stimulatory for human iNKT cells and thus warrants further examination as a potential immunomodulatory agent for human disease.

UR - http://www.scopus.com/inward/record.url?scp=33846469009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846469009&partnerID=8YFLogxK

M3 - Article

C2 - 17237389

AN - SCOPUS:33846469009

VL - 178

SP - 1415

EP - 1425

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 3

ER -